`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`DR. REDDY’S LABORATORIES S.A. and
`DR. REDDY’S LABORATORIES, INC.
`Petitioners,
`
`v.
`
`MONOSOL RX, LLC
`Patent Owner
`
`
`
`
`
`
`
`Case No. IPR2017-01582
`Patent No. 8,603,514
`
`
`
`
`
`
`
`
`PETITIONERS’ REPLY IN SUPPORT OF THE MOTION FOR JOINDER
`WITH IPR2017-00200
`
`
`
`
`
`
`
`
`
`
`
`I.
`
`INTRODUCTION
`
`Monosol RX, LLC (“Patent Owner”) opposed Dr. Reddy’s Laboratories,
`
`S.A. and Dr. Reddy’s Laboratories, Inc.’s (collectively, “DRL” or “Petitioners”)
`
`Motion for Joinder of its proceeding, IPR2017-01582, with Mylan Technologies
`
`Inc.’s (“Mylan”) IPR2017-00200 (“the ’200 IPR”) because, at the time that DRL
`
`filed its Motion for Joinder, DRL and Mylan had not yet finalized an agreement to
`
`cooperate in a joint IPR proceeding. At the same time, Monosol did not oppose a
`
`nearly identical motion for joinder by Par Pharmaceutical, Inc. (“Par”) based on a
`
`representation by Par that it had an agreement to cooperate with Mylan. As
`
`foreshadowed in DRL’s opening brief, Mylan and DRL have now finalized their
`
`agreement to cooperate in a joint IPR proceeding, and Mylan does not oppose
`
`DRL’s motion for joinder. DRL’s agreement with Mylan and Par’s agreement
`
`with Mylan (as described by Patent Owner) each provides the same conditions for
`
`joinder, with DRL and Par each adopting the familiar “understudy” role of a joined
`
`petitioner.
`
`
`
`DRL’s agreement with Mylan addresses every valid concern raised by
`
`Patent Owner in its Opposition to Petitioners’ Motion for Joinder, and effectively
`
`moots the opposition. The Board should therefore grant Petitioners’ motion.
`
`1
`
`
`
`
`II. ARGUMENT
`
`Patent Owner’s principal argument in opposition to Petitioners’ Motion for
`
`Joinder was that, since Mylan and DRL had not agreed on the conditions under
`
`which a joined IPR would proceed, joinder of DRL to the ’200 IPR would delay
`
`the “just, speedy, and inexpensive” resolution of that proceeding. (Opposition, at
`
`12.) DRL’s agreement with Mylan ensures that joining DRL would not interfere
`
`with the schedule of the ’200 IPR and would not delay resolution.
`
`Under Mylan and DRL’s agreement, DRL will take the familiar
`
`“understudy” role of a petitioner joined to an instituted IPR. Specifically, DRL has
`
`agreed that, so long as Mylan remains a party to the IPR: (1) DRL will rely on the
`
`expert declaration of Mylan’s expert in the ’200 IPR; (2) DRL will not receive any
`
`separate cross examination or redirect time during witness depositions, and cross
`
`examinations will occur within the timeframe normally allotted by the Board’s
`
`rules to one party; and (3) DRL will incorporate its filings with those of Mylan in
`
`consolidated filings, subject to the Board’s rules for one party on page limits. DRL
`
`further agrees to adopt a silent role in all communications with the Board and at the
`
`oral hearing for the joined proceeding.
`
`DRL’s Petition presents the same ground of unpatentability that was
`
`instituted in the ’200 IPR, and relies on the same documentary evidence, with the
`
`exception of the expert declaration. Along with its Petition, DRL relied on the
`
`2
`
`
`
`
`declaration of its own expert who offered testimony that is nearly identical to the
`
`testimony offered by Mylan’s expert declarant in the ’200 IPR. DRL understands
`
`that, upon joinder with the ’200 IPR, the instant IPR proceeding will be terminated
`
`and DRL’s expert declaration will not be of record in the joined proceeding. DRL
`
`therefore has received Mylan’s consent to retain Mylan’s declarant, Dr. Buckton,
`
`to work with DRL for purposes of the joined IPR. Since DRL will not have any
`
`expert that is not also an expert for Mylan, joining DRL will not necessitate any
`
`further depositions and will therefore not affect the schedule for the ’200 IPR.
`
`Par has also filed a petition challenging the patentability of the ’514 patent,
`
`along with a motion for joinder with the ’200 IPR. Patent Owner has stated that it
`
`does not oppose Par’s motion for joinder because Par agreed with Mylan to play an
`
`understudy role in the joined IPR, and its participation would therefore not affect
`
`the schedule of the ’200 IPR. (Opposition, at 9-10 and note 4.) Because DRL has
`
`agreed to play an understudy role in the joined proceeding, identical to the
`
`understudy role that Par has agreed to play in the joined proceeding (compare the
`
`terms listed above with the terms listed in Par’s Motion for Joinder, IPR2017-
`
`01557, Paper 4, at 5-6), Patent Owner’s concerns regarding joinder of DRL are
`
`addressed.
`
`For all of the reasons stated in Petitioner’s Motion for Joinder, joining DRL
`
`to the ’200 IPR would further the Board’s “policy preference for joining a party
`
`3
`
`
`
`
`that does not present new issues that might complicate or delay an existing
`
`proceeding.” Enzymotec Ltd. v. Neptune Techs & Bioresources, Inc., IPR2014-
`
`00556, Paper 19 at 6 (P.T.A.B. Jul. 9, 2014). The decisions that Patent Owner
`
`cites in its Opposition, having entirely different factual patterns than those present
`
`here, do not instruct otherwise. In Samsung Elects. Co. v. Affinity Labs of Texas,
`
`LLC, IPR2015-00820, Paper 12 (P.T.A.B. May 15, 2015), the Board denied joinder
`
`for Samsung’s fourth petition for IPR of the same patent, after having granted each
`
`of the first three petitions. In both LG Elects. Inc. v. ATI Techs. ULD, IPR2015-
`
`01620, Paper 10 (P.T.A.B. Feb. 2, 2016) and Reloaded Games, Inc. v. Parallel
`
`Networks, LLC, IPR2014-00950, Paper 12 (P.T.A.B. Oct. 22, 2014), the Board
`
`denied petitioner’s motion to join an IPR in which it was itself the petitioner. The
`
`second petition relied on different grounds and concerned different claims than
`
`were involved in the already-instituted IPR. Thus, joinder would have added new
`
`issues into the instituted IPR. And, in Ubisoft, Inc. v. Uniloc USA, Inc., IPR2016-
`
`00414, Paper 16 (P.T.A.B. Jun. 2, 2016), the Board denied joinder to an IPR that
`
`had already been terminated (and it was petitioner’s third petition; the first IPR had
`
`reached a final written decision and the first CBM had been denied institution).
`
`In this case, DRL’s petition presents only challenges identical to those that
`
`are already instituted by the Board. Joinder is therefore appropriate because it will
`
`4
`
`
`
`
`promote efficient and consistent resolution of the unpatentability grounds at issue
`
`and will not prejudice any of the parties to the ’200 IPR.
`
`III. CONCLUSION
`
`DRL’s agreement with Mylan addresses all of Patent Owner’s concerns
`
`regarding the schedule for the ’200 IPR, and DRL’s joinder will not, in any way,
`
`affect the just, speedy, and inexpensive resolution of the proceeding. Joinder is
`
`therefore appropriate under 37 C.F.R. § 42.1(b) and under the Board’s precedent.
`
`Petitioners respectfully request that the Board grant their Motion for Joinder with
`
`the ’200 IPR.
`
`
`
`
`
`
`
`
`
`
`
`Dated: July 26, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`
`Respectfully submitted,
`
`
`
`/Ira J. Levy/
`Ira J. Levy (Reg. No. 35,587)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Tel.: 212-459-7456
`Fax: 646-558-4143
`ILevy@goodwinlaw.com
`
`Counsel for Petitioners Dr. Reddy’s
`Laboratories S.A. and Dr. Reddy’s
`Laboratories, Inc.
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that this “PETITIONERS’ REPLY IN
`
`
`
`SUPPORT OF THE MOTION FOR JOINDER WITH IPR2017-00200” was
`
`served on this 26th day of July 2017 on Patent Owner by email to Patent Owner’s
`
`counsel of record at the following addresses provided in Patent Owner’s
`
`Mandatory Notices:
`
`hfox@steptoe.com
`514MIPR@steptoe.com
`
`
`
`Courtesy copies of the foregoing were also served on counsel for Mylan in
`
`the ’200 IPR by email at the following addresses provided in Mylan’s Mandatory
`
`Notices in that proceeding:
`
`
`
`
`
`
`
`
`
`
`
`
`/Sarah Fink/
`Sarah Fink (Reg. No. 64,886)
`
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
`
`Dated: July 26, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`